dvm360 Covers Aaron Schacht’s Appointment to Gallant Board
by Gallant Staff
dvm360 included Gallant in its February 2024 roundup of leadership appointments across the veterinary industry.
From dvm360
Paws and profits: Highlighting new promotions in veterinary business
This coverage announces the appointment of Aaron Schacht to Gallant’s Board of Directors. Schacht brings decades of experience from leadership roles at BiomEdit, Elanco, and Eli Lilly. His addition to the board reflects Gallant’s continued focus on building strong executive leadership as the company advances toward potential FDA-labeled stem cell therapies for pets.
